Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 15/20 | 0.67 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083595 | 0.86 | TRPV1 (0.79) | TRPV1EGLN1JAK2JAK1TYK2 | |
| SCHEMBL14083354 | 0.85 | TRPV1 (0.79) | TRPV1EGLN1JAK2JAK1TYK2 | |
| SCHEMBL6364274 | 0.85 | TRPV1 (0.74) | TRPV1 | |
| SCHEMBL6363987 | 0.83 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL4814175 | 0.81 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL14083162 | 0.81 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL14083327 | 0.80 | TRPV1 (0.61) | TRPV1EGLN1 | |
| SCHEMBL14083938 | 0.79 | TRPV1 (0.79) | TRPV1 | |
| SCHEMBL14083602 | 0.77 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL14083367 | 0.75 | TRPV1 (0.64) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005073193-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165015-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885EGLN1 4201/4885JAK2 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.